Bankruptcy court admits BSE-listed Supha Pharmachem under Insolvency Resolution Process

The Mumbai bench of the National Company Law Tribunal has admitted Supha Pharmachem into the Corporate Insolvency Resolution Process (CIRP) over a payment default, and appointed Rajesh Jhunjhunwala as interim resolution professional.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JNAOf7X
via IFTTT

Read More

Regulator steps up oversight of GLP-1 drug distribution chain

India's drug regulatory body is intensifying its scrutiny of the distribution channels for GLP-1 weight loss drugs. State drug authorities are directed to ensure stringent compliance with approved protocols and accurate product labeling. Any instances of unauthorized sale or marketing will invite strict legal action. The agency is also keeping a close watch on promotional activities across different platforms.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/DuZS9q6
via IFTTT

Read More

Biocon not to rush generic semaglutide to packed India market, says incoming CEO Shreehas Tambe

Biocon will delay its Indian launch of semaglutide. The company is focusing on international markets for the diabetes and weight-management drug. Biocon aims to become a global medicines company driven by innovation. Insulin remains a strategic anchor. Oncology and immunology are key pillars. New areas like ophthalmology are being explored. Investments will target technology and AI.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rUT1ZgG
via IFTTT

Read More

Zydus Wellness taps Milind Soman as brand ambassador for Glucon-D recharge

Zydus Wellness has appointed actor Milind Soman as the brand ambassador for its new product, Glucon-D Recharge. This marks the company's entry into the performance hydration category. Glucon-D Recharge is designed to help Indians stay active consistently. The product is available in ready-to-drink bottles and sachet sticks. This expansion caters to evolving consumer needs beyond traditional energy powders.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SQft7XR
via IFTTT

Read More

India’s urban health alarm: One in five at early heart risk, 25% face respiratory threat

Urban Indians are facing a health crisis. Cardiovascular and respiratory risks are rising. Poor air quality, long commutes, and inactivity contribute to these issues. Many are overweight or obese. Young adults show early warning signs. Early awareness is crucial for health and financial planning. This assessment highlights the combined impact of daily stressors on long-term health outcomes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aKnVBAU
via IFTTT

Read More

Painkiller, antibiotic prices set for marginal increase starting April 1

Starting April 1, the prices of essential medicines will experience an increase of 0.6%. This change aligns with the annual alterations in the Wholesale Price Index. Approximately 1,000 medications listed in the National List of Essential Medicines will be impacted.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cx4GEPq
via IFTTT

Read More

US-based Warburg Pincus in talks to buy Maneesh Pharma unit in Rs 1,800 crore deal

US private equity firm Warburg Pincus is nearing a deal to buy Maneesh Pharmaceuticals' non-tuberculosis drug business. The acquisition is valued between ₹1,600 to ₹1,800 crore. This move is part of Warburg's strategy to build a larger pharmaceutical platform in India. A formal announcement is anticipated in the coming months.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/J6oL8TN
via IFTTT

Read More